Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis.

BACKGROUND Amyotrophic lateral sclerosis (ALS) is a chronic degenerative neurologic disorder characterized by the death of motor neurons in the cerebral cortex and spinal cord. Recent studies have suggested that the metabolism of glutamate, a potentially neurotoxic amino acid, is abnormal in patients with ALS. We hypothesized that the high-affinity glutamate transporter is the site of the defect. METHODS We measured high-affinity, sodium-dependent glutamate transport in synaptosomes from neural tissue obtained from 13 patients with ALS, 17 patients with no neurologic disease, and 27 patients with other neuro-degenerative diseases (Alzheimer's disease in 15 patients and Huntington's disease in 12 patients). The groups were comparable with respect to age and the interval between death and autopsy. Synaptosomes were prepared from spinal cord, motor cortex, sensory cortex, visual cortex, striatum, and hippocampus. We also measured sodium-dependent transport of gamma-aminobutyric acid and phenylalanine in the synaptosomal preparations. RESULTS In patients with ALS, there was a marked decrease in the maximal velocity of transport for high-affinity glutamate uptake in synaptosomes from spinal cord (-59 percent, P less than 0.001), motor cortex (-70 percent, P less than 0.001), and somatosensory cortex (-39 percent, P less than 0.05), but not in those from visual cortex, striatum, or hippocampus. The affinity of the transporter for glutamate was not altered. No abnormalities in glutamate transport were found in synaptosomes from patients with other chronic neurodegenerative disorders. The transport of gamma-aminobutyric acid and phenylalanine was normal in patients with ALS. CONCLUSIONS ALS is associated with a defect in high-affinity glutamate transport that has disease, region, and chemical specificity. Defects in the clearance of extracellular glutamate because of a faulty transporter could lead to neurotoxic levels of extracellular glutamate and thus be pathogenic in ALS.

[1]  Jeffrey D. Rothstein,et al.  Reductions in acidic amino acids andN-acetylaspartylglutamate in amyotrophic lateral sclerosis CNS , 1991, Brain Research.

[2]  J. Coyle,et al.  Excitatory amino acids in amyotrophic lateral sclerosis: An update , 1991, Annals of neurology.

[3]  M. Hunter-Ensor,et al.  Pharmacologically distinct sodium-dependentl-[3H]glutamate transport processes in rat brain , 1991, Brain Research.

[4]  E. Perry,et al.  The quantitative autoradiographic distribution of [3H]MK-801 binding sites in the normal human spinal cord , 1991, Brain Research.

[5]  D. Attwell,et al.  The release and uptake of excitatory amino acids. , 1990, Trends in pharmacological sciences.

[6]  G. Urca,et al.  Neurotoxic effects of excitatory amino acids in the mouse spinal cord: quisqualate and kainate but not N-methyl-l-aspartate induce permanent neural damage , 1990, Brain Research.

[7]  J. Coyle,et al.  Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis , 1990, Annals of neurology.

[8]  A. Guidotti,et al.  Abusive stimulation of excitatory amino acid receptors: a strategy to limit neurotoxicity , 1990, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[9]  Dennis P. Nelson,et al.  Activation of Glutamate Dehydrogenase by Leucine and Its Nonmetabolizable Analogue in Rat Brain Synaptosomes , 1990, Journal of neurochemistry.

[10]  R. Currier,et al.  Morphometric studies in dominant olivopontocerebellar atrophy. Comparison of cell losses with amino acid decreases. , 1990, Archives of neurology.

[11]  L. Ziskind-Conhaim,et al.  NMDA receptors mediate poly- and monosynaptic potentials in motoneurons of rat embryos , 1990, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[12]  T. Perry,et al.  What excitotoxin kills striatal neurons in Huntington's disease? Clues from neurochemical studies , 1990, Neurology.

[13]  D. Choi,et al.  The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death. , 1990, Annual review of neuroscience.

[14]  D. Choi,et al.  Neurotoxicity ofβ-N-methylamino-l-alanine (BMAA) andβ-N-oxalylamino-l-alamine (BOAA) on cultured cortical neurons , 1989, Brain Research.

[15]  J. Deakin,et al.  Regional changes in [3H]d-aspartate and [3H]TCP binding sites in Alzheimer's disease brains , 1988, Brain Research.

[16]  E. J. Fletcher,et al.  Quinoxalinediones selectively block quisqualate and kainate receptors and synaptic events in rat neocortex and hippocampus and frog spinal cord in vitro , 1988, British journal of pharmacology.

[17]  D. Choi,et al.  Glutamate neurotoxicity and diseases of the nervous system , 1988, Neuron.

[18]  A. Plaitakis,et al.  The neuroexcitotoxic amino acids glutamate and aspartate are altered in the spinal cord and brain in amyotrophic lateral sclerosis , 1988, Annals of neurology.

[19]  J. Penney,et al.  NMDA receptor losses in putamen from patients with Huntington's disease. , 1988, Science.

[20]  M. Yahr,et al.  PILOT TRIAL OF BRANCHED-CHAIN AMINOACIDS IN AMYOTROPHIC LATERAL SCLEROSIS , 1988, The Lancet.

[21]  T. Perry,et al.  Brain glutamate deficiency in amyotrophic lateral sclerosis , 1987, Neurology.

[22]  J. Swann,et al.  Analysis of aspartate and glutamate in human cerebrospinal fluid by high-performance liquid chromatography with automated precolumn derivatization. , 1986, Analytical biochemistry.

[23]  J. Hardy,et al.  Uptake of γ‐Aminobutyric Acid and Glycine by Synaptosomes from Postmortem Human Brain , 1986 .

[24]  P. Nunn,et al.  Comparative toxicities of α- and β-N-oxalyl-l-α,β-diaminopropionic acids to rat spinal cord , 1985, Neuroscience Letters.

[25]  P. Roberts,et al.  Neurotoxicity of L‐Glutamate and DL‐Threo‐3‐Hydroxyaspartate in the Rat Striatum , 1985, Journal of neurochemistry.

[26]  J D Rothstein,et al.  Glial and neuronal glutamate transport following glutamine synthetase inhibition. , 1985, Biochemical pharmacology.

[27]  R. Tallarida,et al.  Manual of Pharmacologic Calculations: With Computer Programs , 1984 .

[28]  F. Fonnum.  Glutamate: A Neurotransmitter in Mammalian Brain , 1984, Journal of neurochemistry.

[29]  F C Rose,et al.  Elevated levels of amino acids in the CSF of motor neuron disease patients. , 1984, Molecular and Chemical Neuropathology.

[30]  R. Schwarcz,et al.  Post-mortem high affinity glutamate uptake in human brain , 1982, Neuroscience.

[31]  Hughes Jt,et al.  Pathology of amyotrophic lateral sclerosis. , 1982 .

[32]  J. H. Quastel,et al.  Kinetics of Cerebral Uptake Processes In Vitro of L‐Glutamine, Branched‐Chain L‐Amino Acids, and L‐Phenylalanine: Effects of Ouabain , 1980, Journal of neurochemistry.

[33]  R. Desnick,et al.  Glutamate dehydrogenase deficiency in three patients with spinocerebellar syndrome , 1980, Annals of neurology.

[34]  S. Vincent,et al.  A comparison of sodium-dependent glutamate binding with high-affinity glutamate uptake in rat striatum , 1980, Brain Research.

[35]  V. Balcar,et al.  Stereospecificity of the inhibition of l‐glutamate and l‐aspartate high affinity uptake in rat brain slices by threo‐3‐hydroxyaspartate , 1977, Journal of neurochemistry.

[36]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.